Results 191 to 200 of about 817,567 (359)

Single and multiple switches, swap and retransitioning among 28,073 biological drug users with inflammatory bowel diseases: results from the Italian VALORE network. [PDF]

Therap Adv Gastroenterol
Pellegrini G, Spini A, Bellitto C, L'Abbate L, Ingrasciotta Y, Soardo F, Leoni O, Mazzone A, Ancona D, Stella P, Cavazzana A, Scapin A, Lopes S, Belleudi V, Ledda S, Carta P, Rossi P, Ejlli L, Sapigni E, Puccini A, Scarpelli RF, De Sarro G, Tuccori M, Gini R, Allotta A, Addario Pollina S, Da Cas R, Bucaneve G, Mangano AMP, Balducci F, Sorrentino C, Senesi I, Bernardi FF, Trama U, Spila Alegiani S, Mayer F, Massari M, Savarino EV, Variola A, Trifirò G.   +39 more
europepmc   +1 more source

A note on an outbreak of malaria among users of injectable drugs. [PDF]

, 1990
Luis Carlos Barradas Barata, Maria Tereza Macoris Andriguetti, Marcia Caraça Cortás, Cleusa Meneguetti   +3 more
openalex  

Are HTLV-II-Seropositive Injection Drug Users at Increased Risk of Bacterial Pneumonia, Abscess, and Lymphadenopathy?

, 1997
Lucy Modahl, Katy C. Young, Karen F. Varney, H Khayam-Bashi, Edward L. Murphy   +4 more
openalex   +1 more source

Large Declines in Sexual Risk Behavior with Noncommercial Partners among Heterosexual Injection Drug Users in Amsterdam, 1989-1995 [PDF]

, 1996
Erik J.C. van Ameijden, J. A. R. d. Van Hoek, R A Coutinho   +2 more
openalex   +1 more source

Researching Hard-to Reach Populations: Privileged Access Interviewers and Drug Using Parents [PDF]

Accessing drug using populations is notoriously fraught with difficulties for researchers (Gurdin & Patterson, 1987; Griffiths, Gosspo & Strang, 1993; Renzetti & Lee, 1993; Spreen & Zwaagstra, 1994; Goode, 2000; Elliott et al., 2002).
Jackie Kearney, Nicola Jane Taylor
core  

The influence of ROS1 fusion partners and resistance mechanisms in ROS1‐TKI‐treated non‐small cell lung cancer patients

Molecular Oncology, EarlyView.
This real‐world study of ROS1+ NSCLC highlights fusion diversity, treatment outcomes with crizotinib and lorlatinib, and in vitro experiments with resistance mechanisms. G2032R drives strong resistance to ROS1‐targeted TKIs, especially lorlatinib. Fusion partner location does not affect overall survival to crizotinib or lorlatinib. Findings support the
Fenneke Zwierenga, Christa Dijkhuizen, Patrick Korthuis, Wim Timens, Harry Groen, Jeroen Hiltermann, Anke van den Berg, Lyndsay Drayer, Anthonie van der Wekken   +8 more
wiley   +1 more source

Burden, Risk Factors, and Knowledge of Non-fatal Opioid Overdose Among Injectable Drug Users: A Cross-sectional Study. [PDF]

Indian J Psychol Med
Das S, Sen S, Mondal S, Mondal M, Khatun Y, Sarkhel S, Saha I, Mukherjee S, Bhowmik K, Sarkar S, Neogi R, Rao R, Paramanik M, Bhattacharjee M, Basu A, Bhargava S, Ganguly S, Bhattacharjee S, Saha A, Chakrabarti A.   +19 more
europepmc   +1 more source

Novel Circovirus in Blood from Intravenous Drug Users, Yunnan, China. [PDF]

Emerg Infect Dis, 2023
Li Y, Zhang P, Ye M, Tian RR, Li N, Cao L, Ma Y, Liu FL, Zheng YT, Zhang C.   +9 more
europepmc   +1 more source

Drugs and Growth-Efficient Prevention: An Inter-temporal Portfolio of Machos, Narcos and Angels [PDF]

In many countries substance abuse is a social epidemic. This paper deals conceptually with some macroeconomic aspects of widespread substance abuse with special reference to narcotic drugs.
Levy, Amnon, Neri, Frank
core  

YAP1::TFE3 mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma

Molecular Oncology, EarlyView.
The YAP1::TFE3 fusion protein drives endothelial‐to‐mesenchymal transition (EndMT) plasticity, resulting in the loss of endothelial characteristics and gain of mesenchymal‐like properties, including resistance to anoikis, increased migratory capacity, and loss of contact growth inhibition in endothelial cells.
Ant Murphy, Samuel Hartzler, Paula A. Vargas Carranza, Shyaman Jayasundara, Madison E. Yates, Nimod D. Janson, Bozhi Liu, Annaleigh Benton, Majid Kazemian, Jason A. Hanna   +9 more
wiley   +1 more source